The Impact of Pharmacist-Managed Service on Warfarin Therapy in Patients after Mechanical Valve Replacement
Table 2
Effectiveness and safety outcomes of study groups.
Outcomes
Conventional group (n = 39)
PMWT group (n = 33)
value
Effectiveness outcomes
Time in therapeutic range (%)
37.1 ± 26.6
44.0 ± 32.4
0.327
Time to therapeutic range (days)
7.6 ± 5.9
6.2 ± 3.9
0.304
Therapeutic INR at discharge
18 (46.2)
24 (72.7)
0.023
Subtherapeutic INR at discharge
18 (46.2)
9 (27.3)
0.099
Supratherapeutic INR at discharge
3 (7.7)
0 (0.0)
0.245
Therapeutic INR at first return appointment†
22 (62.9)
22 (71.0)
0.485
Length of stays (days)
18.9 ± (14.7)
16.4 ± (9.5)
0.789
Safety outcome
Supratherapeutic INR during hospital stay
14 (35.9)
3 (9.1)
0.008
Distribution of supratherapeutic INR
3 < INR ≤ 5
12 (85.7)
1 (33.3)
0.002
5 < INR ≤ 9
2 (14.3)
1 (33.3)
1.000
INR ≥ 9
0 (0)
1 (33.3)
0.458
Data are represented as the number of patients (%) or mean ± SD. Statistically significant (). INR, international normalized ratio; PMWT, pharmacist-managed warfarin therapy; SD, standard deviation. †A total of 4 patients in the conventional group and 2 patients in the PMWT group did not return to the first outpatient appointment after discharge.
